arnoldpartners.com
Recent Placements Archives - arnoldpartners.com
http://arnoldpartners.com/category/placements
Arnold Partners’ 2015 Year in Review. January 19, 2016. 2015 proved to be another very busy and productive year for Arnold Partners. We proudly placed almost as many female executives as male in the last two years. We served seven different industry sectors with our eight completed searches in 2015, and even completed a VP HR search to end the year! The market continued to be strong in 2015, and despite some global headwinds, we expect 2016 to be another year with continued demand for financial talent.
sambrown.com
Sam Brown Inc. Biotechnology, Pharmaceutical and Healthcare Corporate Communications
http://www.sambrown.com/index.html
Demand more. We do. Sam Brown Inc. Healthcare Communications. We understand. You are under pressure to deliver more value, meet higher standards. Shouldn’t you demand the same from your agency? At Sam Brown Inc., we feel personally responsible for your success. We get healthcare all players in all sectors. We custom tailor your team and strategies to fit your needs and achieve your specific goals. For the best teams, proven results and personalized service, talk to Sam Brown Inc. Like Us on Facebook.
nizetlab.ucsd.edu
Nizet Lab: Scientific Collaborations
http://nizetlab.ucsd.edu/Collaborations
COLLABORATIONS HERE AT UCSD. Richard Gallo, MD, PhD. Professor of Medicine and Pediatrics. Chief, Division of Dermatology. Skin Innate Immunity, Cathelicidin Antimicrobial Peptides. Ajit Varki, MD. Distinguished Professor of Medicine and Cellular and Molecular Medicine. Sialic Acids and Siglecs in Bacterial Host-Pathogen Interactions. Michael Karin, PhD. Distinguished Professor of Pharmacology. Innate Immunity, NF k. B/IKK and Inflammasome Signaling. Partho Ghosh, PhD. Pieter Dorrestein, PhD. Development...
5amventures.com
5AM Ventures | Portfolio
http://5amventures.com/portfolio
THE 5AM PORTFOLIO: COMPANY PROFILES. Achaogen (AKAO) is a biopharmaceutical company developing small molecule therapeutics to treat infections caused by multi-drug resistant bacterial. IPO in March 2014. Alexza (ALXA) is a biopharmaceutical company developing drugs for local and systemic delivery through the lung. IPO in March 2006. Aprea is a biopharmaceutical company developing small molecule therapeutics for the treatment of cancer by reactivating mutant p53 tumor suppressor function. Calibrium is a b...
SOCIAL ENGAGEMENT